Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Torisel

- PMLiVE

Pfizer shares positive late-stage results for RSV vaccine Abrysvo in high-risk adults

There are currently no vaccines approved for use in adults aged 18 to 59 years

- PMLiVE

Pfizer’s antibiotic combination receives CHMP recommendation to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Pfizer/Astellas’ Xtandi receives CHMP recommendation to treat recurrent prostate cancer

For nine out of ten patients with nmHSPC with high-risk BCR, their condition will progress into a metastatic disease

- PMLiVE

New technique enables study of immune response to cancer using archived tissue samples

FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples

- PMLiVE

Pfizer’s 20-valent pneumococcal vaccine receives EC approval for infants and children

The 20 serotypes included in Prevenar 20 cause the majority of circulating pneumococcal disease

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

- PMLiVE

Pfizer’s Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis

The immune-mediated inflammatory bowel disease affects approximately 300,000 people in the UK

- PMLiVE

Ipsen’s Cabometyx and BMS’ Opdivo recommended by NICE for advanced kidney cancer

The decision could benefit approximately 2,287 patients with renal cell carcinoma annually

- PMLiVE

Gilead and Merus announce oncology partnership worth over $1.5bn

The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies

- PMLiVE

Pfizer’s RSV vaccine Abrysvo shown to maintain strong efficacy in older adults

RSV infections account for up to 160,000 hospitalisations among older adults each year in the US

- PMLiVE

Researchers develop screening tool to investigate mechanisms behind multiple diseases

The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links